What are the currently approved FDA bispecific antibody therapies in multiple myeloma treatment?

As of July 2024, there are three FDA-approved bispecific antibody therapies available to treat multiple myeloma. 

Several bispecific antibodies are in clinical trials and are expected to be approved within the next 2-3 years. This guide will be updated as more bispecific antibodies are approved. 

The three currently approved therapies are: 

• Teclistamab (TECVAYLI), manufactured by Johnson&Johnson, approved in October 2022
• Elranatamab (ELREXFIO), manufactured by Pfizer, approved in August 2023  
• Talquetamab (TALVEY), manufactured by Johnson&Johnson, approved in August 2023  

Although commercially available, these therapies might also be received through a clinical trial, as they are being tested in a wider population and combined with other myeloma treatments (See Treatment Strategies with Bispecific Antibodies).

There are certain differences between each of these medications that may affect which one your doctor recommends.

Keep in mind that these medications have never been directly compared against one another in a research trial. As a result, the exact numbers reported (such as response rates or rates of certain symptoms) cannot be directly compared as each of the trials studying these medications used slightly different methods and different patient populations.